Xencor to Present at the SVB Securities Global Biopharma Conference
08 February 2023 - 8:01AM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced that
company management will present at the virtual 2023 SVB Securities
Global Biopharma Conference on Tuesday, February 14, 2023, at 3:40
p.m. ET / 12:40 p.m. PT.
A live webcast of the presentation will be available under
"Events & Presentations" in the Investors section of the
Company's website located at www.xencor.com. After the webcast, a
replay will be archived on the website for at least 30 days.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230207006059/en/
Charles Liles cliles@xencor.com 626-737-8118
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Apr 2023 to Apr 2024